{"id":9153,"date":"2025-11-10T16:39:07","date_gmt":"2025-11-10T13:39:07","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9153"},"modified":"2025-11-10T16:39:07","modified_gmt":"2025-11-10T13:39:07","slug":"what-primary-care-doctors-need-to-know-about-the-new-blood-pressure-guidelines-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/what-primary-care-doctors-need-to-know-about-the-new-blood-pressure-guidelines-2025\/","title":{"rendered":"What Primary Care Doctors Need to Know About the New Blood Pressure Guidelines 2025"},"content":{"rendered":"
What Primary Care Doctors Need to Know About the New Blood Pressure Guidelines 2025<\/div>\n
<\/div>\n
Source: Medscape, October 31, 2025<\/div>\n
<\/div>\n
Introduction:<\/div>\n
Clinical Guidelines of the American College of Cardiology (ACC) on Hypertension.<\/div>\n
This update is especially relevant for general practitioners (GPs), emergency physicians (ER doctors), internists, and family doctors \u2014 the frontline clinicians who manage nearly 90% of patients presenting with elevated blood pressure at their first medical visit- the frontline clinicians who manage nearly 90% of patients presenting with elevated blood pressure or hypertension at their first medical encounter.<\/div>\n
Keynotes:<\/div>\n
1. New Hypertension Target:<\/span><\/div>\n
The American College of Cardiology (ACC) and American Heart Association (AHA) now recommend a blood\u2026<\/div>\n
[10:12 PM, 11\/8\/2025] Dr Jamal Aldabbas Card Socity: Additional Clinical Perspectives and Key Additions \u2013 2025 ACC\/AHA Hypertension Guidelines<\/div>\n
<\/div>\n
Source: Supplementary Commentary: Published by the Jordanian Cardiac Society (JCS) on its official platforms at the time of the guideline release in August, based on the (ACC)& (AHA) Hypertension Guidelines, 2025.<\/div>\n
<\/div>\n
Date: November 2025<\/div>\n
Target Audience: Primary-care physicians, emergency physicians, internists, and cardiologists.<\/div>\n
<\/div>\n
Keynotes:<\/div>\n
1. PREVENT Risk Calculator \u2013 Core Variables and Treatment Thresholds<\/div>\n
\u2022 The PREVENT score replaces the former scores for estimating cardiovascular risk.<\/span><\/div>\n
\u2022 Based on over 3 million contemporary adults (2008\u20132022), reflecting modern demographics and treatment patterns.<\/span><\/div>\n
\u2022 Calculates both 10-year and 30-year CVD risk.<\/span><\/div>\n
\u2022 Treatment in Stage 1 hypertension (130\u2013139 \/ 80\u201389 mm Hg) should be initiated if PREVENT 10-year risk \u2265 7.5 % or if comorbidities exist (diabetes, CKD, ASCVD).<\/span><\/div>\n
\u2022 Core variables included:<\/span><\/div>\n
1. Age, sex, race\/ethnicity<\/span><\/div>\n
2. Systolic and diastolic blood pressure<\/span><\/div>\n
3. Total cholesterol and HDL-cholesterol<\/span><\/div>\n
4. Diabetes status<\/span><\/div>\n
5. Smoking (tobacco use)<\/span><\/div>\n
6. Body-mass index (BMI)<\/span><\/div>\n
7. Chronic kidney disease (CKD)<\/span><\/div>\n
8. Education \/ social deprivation index<\/span><\/div>\n
9. Use of antihypertensive therapy<\/span><\/div>\n
10. Reproductive history (gestational hypertension or preterm birth in women)<\/span><\/div>\n
\u2022 Access link: https:\/\/professional.heart.org\/en\/guidelines-and-statements\/prevent-risk-calculator<\/span><\/div>\n
<\/div>\n
2. Pregnancy and Post-Partum Hypertension<\/div>\n
\u2022 Initiate pharmacologic therapy when BP \u2265 140\/90 mm Hg.<\/span><\/div>\n
\u2022 Preferred agents: labetalol, extended-release nifedipine, or methyldopa.<\/span><\/div>\n
\u2022 Contraindicated: ACE inhibitors, ARBs, and direct renin inhibitors.<\/span><\/div>\n
\u2022 Target BP: Maintain < 140\/90 mm Hg; avoid excessive lowering (< 130 mm Hg) to prevent placental hypoperfusion.<\/span><\/div>\n
\u2022 Monitoring:<\/span><\/div>\n
\u2022 Measure BP within 72 h postpartum,<\/span><\/div>\n
\u2022 Repeat at 7\u201310 days, then 6\u201312 weeks.<\/span><\/div>\n
\u2022 Classification: Persistent hypertension beyond 12 weeks = chronic hypertension.<\/span><\/div>\n
\u2022 Long-term impact: Hypertensive disorders of pregnancy and pre-eclampsia are now major cardiovascular risk enhancers in the PREVENT model.<\/span><\/div>\n
<\/div>\n
3. Central Nervous System (CNS) and Cerebrovascular Disease<\/div>\n
\u2022 Hypertension is the leading modifiable factor for stroke, intracerebral hemorrhage (ICH), and cognitive decline.<\/span><\/div>\n
<\/div>\n
A. Acute Ischemic Stroke<\/div>\n
1. Before thrombolysis\/thrombectomy: reduce BP < 185\/110 mm Hg.<\/span><\/div>\n
2. Without reperfusion therapy: treat only if SBP > 220 or DBP > 120 mm Hg.<\/span><\/div>\n
3. Post-reperfusion: maintain < 180\/105 mm Hg for 24 h.<\/span><\/div>\n
<\/div>\n
B. Intracerebral Hemorrhage (ICH)<\/div>\n
1. Lower systolic BP rapidly but safely to \u2248 140 mm Hg within 1 hour.<\/span><\/div>\n
2. Avoid reductions < 110 mm Hg.<\/span><\/div>\n
3. IV options: nicardipine, clevidipine, or labetalol.<\/span><\/div>\n
<\/div>\n
C. Long-Term Prevention<\/div>\n
\u2022 Maintain BP < 130\/80 mm Hg post-stroke or TIA.<\/span><\/div>\n
\u2022 Tight control reduces recurrence, cognitive decline, and dementia.<\/span><\/div>\n
<\/div>\n
4. Additional Organ Protection and Screening<\/div>\n
\u2022 Urine albumin-to-creatinine ratio (UaCr): mandatory at diagnosis and follow-up.<\/span><\/div>\n
\u2022 Primary hyperaldosteronism: screen in resistant, early-onset, or severe hypertension.<\/span><\/div>\n
\u2022 Microvascular protection: include renal, retinal, and cerebral monitoring.<\/span><\/div>\n
\u2022 Cognitive health: sustained systolic < 130 mm Hg helps delay small-vessel disease.<\/span><\/div>\n
<\/div>\n
5. Clinical Note \u2013 Immediate-Release Oral Nifedipine<\/div>\n
<\/div>\n
Immediate-release oral (Not SL)nifedipine may be used only in pregnancy-related severe hypertension (\u2265 160\/110 mm Hg) as a safe, rapid option when IV access is unavailable.<\/div>\n
<\/div>\n
Outside pregnancy, it should not be used for hypertensive emergencies and is rarely appropriate for urgencies; safer oral or IV agents (labetalol, captopril, clonidine, nicardipine) are preferred to avoid abrupt, harmful BP reductions.<\/div>\n
<\/div>\n
6. Key Take-Home Points<\/div>\n
1. BP Target: < 130\/80 mm Hg for most adults; individualize for frail or pregnant patients.<\/span><\/div>\n
2. Risk Assessment: Use PREVENT score (\u2265 7.5 % = pharmacologic threshold).<\/span><\/div>\n
3. Pregnancy: Treat at 140\/90 mm Hg; avoid RAAS blockers; monitor postpartum.<\/span><\/div>\n
4. CNS:<\/span><\/div>\n
\u2022 Thrombolysis: < 185\/110 mm Hg<\/span><\/div>\n
\u2022 Intracerebral hemorrhage: \u2248 140 mm Hg<\/span><\/div>\n
\u2022 Long-term: < 130\/80 mm Hg<\/span><\/div>\n
5. Organ Protection: Routine UaCr, endocrine screening, cognitive follow-up.<\/span><\/div>\n
6. Lifestyle: Weight, diet, physical activity, and smoking cessation remain fundamental.<\/span><\/div>\n
<\/div>\n
Jordan Cardiac Society (JCS)<\/div>\n
\ud83c\udf10 www.jordan-cardiac.org<\/div>\n
\ud83d\udd17 http:\/\/jordaniancs.ecardroots.com<\/a><\/div>\n
Date: November 2025<\/div>\n","protected":false},"excerpt":{"rendered":"

What Primary Care Doctors Need to Know About the New Blood Pressure Guidelines 2025 Source: Medscape, October 31, 2025 Introduction: Clinical Guidelines of the American College of Cardiology (ACC) on Hypertension. This update is especially relevant for general practitioners (GPs), emergency physicians (ER doctors), internists, and family doctors \u2014 the frontline clinicians who manage nearly […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9153","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9153"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9153\/revisions"}],"predecessor-version":[{"id":9154,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9153\/revisions\/9154"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}